GRP78 mRNA levels were shown to be four times more likely in the blood of COVID-19 (+ve) pneumonia patients than COVID-19 (−ve) pneumonia patients, suggesting that GRP78 could be a potential molecular target for developing COVID-19 treatment. This evidence concerns the gene HSPA5 and pneumonia.